History of Migraine and Risk of COVID-19: A Cohort Study - 20/10/23
, Julie E. Buring, ScD a, b, JoAnn E. Manson, MD, DrPH a, b, Howard D. Sesso, ScD a, b, 1, Tobias Kurth, MD, ScD b, c, 1
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Although studies have reported migraine and headache as common symptoms of COVID-19, little is known about the association between migraine and the risk of developing COVID-19.
Methods |
This is a prospective cohort study among 16,492 women enrolled in the Women's Health Study who completed a series of questionnaires in 2020 and 2021 concerning the COVID-19 pandemic. We defined history of migraine as reporting a physician diagnosis of migraine on any of the annual questionnaires from enrollment into the study (1992-1995) through the end of 2019. Individuals were classified as having had COVID-19 if they reported a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its antibodies, were told by a health care provider that they were probably or definitely diagnosed with COVID-19, or were hospitalized for COVID-19. We used logistic regression with inverse probability weighting to adjust for differences in the probability of being tested for SARS-CoV-2 and potential confounding.
Results |
There were 4759 women (28.9%) that reported any history of migraine through the end of 2019; 1271 women were classified as having COVID-19, including 394 cases among those with a history of migraine. We did not observe evidence of a strong or moderate association between history of migraine and the risk of having had COVID-19 (odds ratio 1.08; 95% confidence interval, 0.95-1.22). Similar results were observed for migraine subtypes as well as for hospitalizations for COVID-19.
Conclusions |
Older women with a history of migraine do not have an appreciable increase in the risk of developing COVID-19.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Epidemiology, Migraine
Plan
| Funding: The Women's Health Study is funded by grants from the National Cancer Institute (CA047988 and UM1 CA182913) and the National Heart, Lung, and Blood Institute (HL043851, HL080467, and HL099355). PMR was supported by a Career Development Award from the National Heart, Lung, and Blood Institute (K01 HL128791). HDS received relevant support from internal funding from Brigham and Women's Hospital, Boston, Mass. |
|
| Conflicts of Interest: PMR, JEB, JEM, and HDS have no disclosures to report; TK reports having received research grants from the Gemeinsamer Bundesausschuss (G-BA – Federal Joint Committee) and the Bundesministerium für Gesundheit (BMG – Federal Ministry of Health). He further has received personal compensation from Eli Lilly & Company, Teva Pharmaceuticals, TotalEnergies S.E., the BMJ, and Frontiers. |
|
| Authorship: All authors had access to the data and a role in writing the manuscript. |
Vol 136 - N° 11
P. 1094-1098 - novembre 2023 Retour au numéro
Article précédent
- Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
- Ronza Najjar-Debbiny, Ofra Barnett-Griness, Johad Khoury, Naomi Gronich, Gabriel Weber, Yochay Adir, Michal Shteinberg, Sonia Shneir, Lokesh Sharma, Walid Saliba
- Machine Learning Predicting Atrial Fibrillation as an Adverse Event in the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
- Ying Gue, Elon Correa, John L.P. Thompson, Shunichi Homma, Min Qian, Gregory Y.H. Lip
Bienvenue sur EM-consulte, la référence des professionnels de santé.